Welcome to the international HTA database

Showing [24038 Records] Selected Records [0 Hits] [Clear]

Year	Source	Title
2014	Canadian Agency for Drugs and Technologies in Health (CADTH)	Ocriplasmin (Jetrea - Alcon Canada Inc.) indication: symptomatic vitreomacular adhesion
2014	NIHR Horizon Scanning Centre (NIHR HSC)	Nivolumab for advanced melanoma – second or third line
2014	Canadian Agency for Drugs and Technologies in Health (CADTH)	Intravenous administration of medications in home care settings: clinical evidence and guidelines
2014	Basque Office for Health Technology Assessment (OSTEBA)	[The development and piloting of a multidisciplinary collaborative program for the comprehensive care of patients diagnosed with heart failure (HF) – PROMIC]
2014	Andalusian Health Technology Assessment Area (AETSA)	[Clinical practice guideline on intravenous therapy with temporary devices in adults]
2014	Canadian Agency for Drugs and Technologies in Health (CADTH)	Clinical review report. Ocriplasmin (Jetrea - Alcon Canada Inc.) indication: symptomatic vitreomacular adhesion
2014	NIHR Horizon Scanning Centre (NIHR HSC)	Nivolumab for BRAF V600 mutation– negative advanced melanoma – first line
2014	Canadian Agency for Drugs and Technologies in Health (CADTH)	Urine testing in long-term care: clinical and cost effectiveness
2014	Andalusian Health Technology Assessment Area (AETSA)	[Guide to clinical practice of care in pregnancy and puerperium]
2014	Canadian Agency for Drugs and Technologies in Health (CADTH)	Pharmacoeconomic review report. Ocriplasmin (Jetrea - Alcon Canada Inc.) indication: symptomatic vitreomacular adhesion
2014	NIHR Horizon Scanning Centre (NIHR HSC)	Nivolumab for BRAF V600 mutation-positive advanced melanoma – first line
2014	Canadian Agency for Drugs and Technologies in Health (CADTH)	Continuous positive airway pressure compared with oral devices or lifestyle changes for the treatment of obstructive sleep apnea: a review of the clinical and cost-effectiveness
2014	NIHR Health Technology Assessment programme	Can rapid integrated Polymerase Chain Reaction (PCR)-based diagnostics for Gastrointestinal pathogens improve routine hospital infection control practice? A diagnostic study
2014	Canadian Agency for Drugs and Technologies in Health (CADTH)	Somatropin (Genotropin - Pfizer Canada Inc.) indication: Turner syndrome
2014	Health Quality Ontario (HQO)	Testing vitamin B12 levels in neuropathy, alopecia, dizziness, and fatigue: a rapid review
2014	NIHR Horizon Scanning Centre (NIHR HSC)	Nivolumab with ipilimumab for advanced melanoma – first line
2014	Canadian Agency for Drugs and Technologies in Health (CADTH)	Parent advisors in pediatric rehabilitation: clinical effectiveness and guidelines
2014	Andalusian Health Technology Assessment Area (AETSA)	[Rapid review. Gender dysphoria. Diagnosis, treatment and health outcomes]
2014	Canadian Agency for Drugs and Technologies in Health (CADTH)	Clinical review report. Somatropin (Genotropin - Pfizer Canada Inc.) indication: Turner syndrome
2014	Health Quality Ontario (HQO)	Preoperative consultation: a rapid review
2014	NIHR Horizon Scanning Centre (NIHR HSC)	Nivolumab for advanced or metastatic clear-cell renal cell carcinoma – second or third line
2014	Canadian Agency for Drugs and Technologies in Health (CADTH)	Universal screening for antibiotic-resistant organisms in long-term care facilities: clinical effectiveness and guidelines
2014	Andalusian Health Technology Assessment Area (AETSA)	[Summary of evidence for efficacy and safety of sofosbuvir in transplant patients with chronic hepatitis c]
2014	NIHR Health Technology Assessment programme	The clinical and cost effectiveness of brief intervention for excessive alcohol consumption among people attending sexual health clinics: a randomised controlled trial (SHEAR)
2014	Canadian Agency for Drugs and Technologies in Health (CADTH)	Pharmacoeconomic review report. Somatropin (Genotropin - Pfizer Canada Inc.) indication: Turner syndrome
2014	Health Quality Ontario (HQO)	Preoperative cardiac stress tests for noncardiac surgery: a rapid review
2014	NIHR Horizon Scanning Centre (NIHR HSC)	Ramucirumab (Cyramza) in combination with docetaxel for locally advanced or metastatic non-small cell lung cancer – second line
2014	Canadian Agency for Drugs and Technologies in Health (CADTH)	Linaclotide
2014	Andalusian Health Technology Assessment Area (AETSA)	[Summary of evidence for efficacy and safety of sofosbuvir in patients with chronic hepatitis c waiting for liver transplant]
2014	NIHR Health Technology Assessment programme	Radium-223 dichloride for treating metastatic hormone relapsed prostate cancer with bone metastases
2014	Canadian Agency for Drugs and Technologies in Health (CADTH)	Pharmacoeconomic review report. Somatropin (Genotropin - Pfizer Canada Inc.) indication: long-term treatment of children who have growth failure due to an inadequate secretion of endogenous growth hormone
2014	Health Quality Ontario (HQO)	Preoperative resting echocardiography for noncardiac surgery: a rapid review
2014	NIHR Horizon Scanning Centre (NIHR HSC)	Ramucirumab for metastatic colorectal cancer – second line
2014	Canadian Agency for Drugs and Technologies in Health (CADTH)	Dexmedetomidine for sedation in the ICU or PICU: a review of cost-effectiveness and guidelines
2014	Andalusian Health Technology Assessment Area (AETSA)	[Summary of evidence for efficacy and safety of sofosbuvir in patients with chronic hepatitis c coinfected with human immunodeficiency virus]
2014	NIHR Health Technology Assessment programme	Enzalutamide for the treatment of metastatic hormone relapsed prostate cancer previously treated with a docetaxel-containing regimen
2014	Canadian Agency for Drugs and Technologies in Health (CADTH)	Clinical review report. Somatropin (Genotropin - Pfizer Canada Inc.) indication: long-term treatment of children who have growth failure due to an inadequate secretion of endogenous growth hormone
2014	Health Quality Ontario (HQO)	Hemoglobin A1c testing in diabetes: a rapid review
2014	NIHR Horizon Scanning Centre (NIHR HSC)	Tasquinimod for chemotherapy naïve, metastatic hormone-relapsed prostate cancer
2014	Canadian Agency for Drugs and Technologies in Health (CADTH)	Autologous blood reinfusion system for orthopedic surgery: clinical and cost-effectiveness
2014	Andalusian Health Technology Assessment Area (AETSA)	[Selection criteria for direct antiviral agents for patients with chronic hepatitis c in a severe clinical situation in the SSPA]
2014	Canadian Agency for Drugs and Technologies in Health (CADTH)	Somatropin (Genotropin - Pfizer Canada Inc.) indication: long-term treatment of children who have growth failure due to an inadequate secretion of endogenous growth hormone
2014	Institute of Health Economics (IHE)	Effectiveness of screening for endemic antibiotic resistant organisms (AROs) in hospital settings
2014	NIHR Horizon Scanning Centre (NIHR HSC)	TH-302 in combination with doxorubicin for locally advanced or metastatic, unresectable soft tissue sarcoma – first line
2014	Canadian Agency for Drugs and Technologies in Health (CADTH)	Extracorporeal membrane oxygenation for acute respiratory failure: a review of the clinical effectiveness and guidelines
2014	Andalusian Health Technology Assessment Area (AETSA)	[Updating of selection criteria for direct antiviral agents for patients with chronic hepatitis c in a severe clinical situation in the SSPA]
2014	NIHR Health Technology Assessment programme	The effectiveness of collaborative care for people with memory problems in primary care: results of the CAREDEM case management modelling and feasibility study
2014	NIHR Horizon Scanning Centre (NIHR HSC)	SpaceOAR® perirectal spacing system for prostate cancer radiation
2014	Canadian Agency for Drugs and Technologies in Health (CADTH)	Vitamin D toxicity associated with different vitamin D dosing regimens: safety
2014	Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S)	Stem cell transplantation for biologic-resistant Crohn's disease
2014	NIHR Health Technology Assessment programme	The opportunities and challenges of pragmatic point-of-care randomised trials using routinely collected electronic records: evaluations of two exemplar trials
2014	Canadian Agency for Drugs and Technologies in Health (CADTH)	Clinical review report. Somatropin (Genotropin - Pfizer Canada Inc.) indication: growth hormone deficiency in adults
2014	NIHR Health Technology Assessment programme	Can rapid integrated polymerase chain reaction-based diagnostics for gastrointestinal pathogens improve routine hospital infection control practice? A diagnostic study
2014	NIHR Horizon Scanning Centre (NIHR HSC)	Macy catheter for rectal drug administration
2014	Canadian Agency for Drugs and Technologies in Health (CADTH)	Extracorporeal membrane oxygenation for cardiac failure: a review of the clinical effectiveness and guidelines
2014	Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S)	Remote presence robots in telemedicine
2014	Canadian Agency for Drugs and Technologies in Health (CADTH)	Pharmacoeconomic review report. Somatropin (Genotropin - Pfizer Canada Inc.) indication: growth hormone deficiency in adults
2014	NIHR Health Technology Assessment programme	The SNAP trial: a randomised placebo-controlled trial of nicotine replacement therapy in pregnancy - clinical effectiveness and safety until 2 years after delivery, with economic evaluation
2014	Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA)	[Acupuncture - areas of application, current evidence and proven indications]
2014	Canadian Agency for Drugs and Technologies in Health (CADTH)	Post-operative cerebrospinal fluid removal: guidelines
2014	Andalusian Health Technology Assessment Area (AETSA)	[Communication strategies with children and adolescents in the hospital or primary care setting]
2014	Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S)	Ablative techniques for the treatment of localised prostate cancer
2014	NIHR Health Technology Assessment programme	The SNAP trial: a randomised placebo-controlled trial of nicotine replacement therapy in pregnancy; effectiveness and safety until 2 years after delivery, with economic evaluation
2014	Canadian Agency for Drugs and Technologies in Health (CADTH)	Lurasidone (Latuda - Sunovion Pharmaceuticals Inc.) indication: schizophrenia
2014	NIHR Health Technology Assessment programme	Clinical effectiveness and cost-effectiveness of cholecystectomy compared with observation/conservative management for preventing recurrent symptoms and complications in adults presenting with uncomplicated symptomatic gallstones or cholecystitis: a systematic review and economic evaluation
2014	NIHR Horizon Scanning Centre (NIHR HSC)	CoVa™ Monitoring System for congestive heart failure
2014	Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA)	Opportunities and strategies to drive appropriate use of MRI in Austria
2014	Canadian Agency for Drugs and Technologies in Health (CADTH)	Islet cell transplantation in patients with unstable diabetes: a review of clinical- and cost-effectiveness and guidelines
2014	Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S)	Theralite for treatment of renal failure in patients with multiple myeloma
2014	NIHR Health Technology Assessment programme	Randomised controlled trial and health economic evaluation of the impact of diagnostic testing for influenza, respiratory syncytial virus and Streptococcus pneumoniae infection on the management of acute admissions in the elderly and high-risk 18- to 64-year olds
2014	Canadian Agency for Drugs and Technologies in Health (CADTH)	Clinical review report. Lurasidone (Latuda - Sunovion Pharmaceuticals Inc.) indication: schizophrenia
2014	NIHR Health Technology Assessment programme	Implantable cardioverter defibrillators for the treatment of arrhythmias and cardiac resynchronisation therapy for the treatment of heart failure: systematic review and economic evaluation
2014	NIHR Horizon Scanning Centre (NIHR HSC)	Kangaroo™ feeding tube with IRIS technology for aid in nasogastric tube placement
2014	Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA)	Idelalisib (Zydelig(R)) in addition to rituximab for the treatment of relapsed chronic lymphocytic leukaemia
2014	Canadian Agency for Drugs and Technologies in Health (CADTH)	Azelastine - HCl and fluticasone propionate
2014	Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S)	Drug-eluting stents with CD34 antibodies for the treatment of coronary artery disease
2014	NIHR Health Technology Assessment programme	Percutaneous vertebroplasty and percutaneous balloon kyphoplasty for the treatment of osteoporotic vertebral fractures: a systematic review and cost-effectiveness analysis
2014	Canadian Agency for Drugs and Technologies in Health (CADTH)	Pharmacoeconomic review report. Lurasidone (Latuda - Sunovion Pharmaceuticals Inc.) indication: schizophrenia
2014	Canadian Agency for Drugs and Technologies in Health (CADTH)	Urine testing in long-term care: guidelines
2014	Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S)	Online programs for weight loss
2014	Canadian Agency for Drugs and Technologies in Health (CADTH)	Lyophilized plasma for the treatment of adults with hemorrhagic shock: clinical and cost-effectiveness, safety, and guidelines
2014	NIHR Horizon Scanning Centre (NIHR HSC)	Aflibercept solution (Eylea) for visual impairment due to macular oedema secondary to branch retinal vein occlusion
2014	Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA)	Vasoprotectives: efficacy and safety of capillary stabilising agents for venous insufficiency or haemorrhoids
2014	Canadian Agency for Drugs and Technologies in Health (CADTH)	Retinal surgeries in non-hospital facilities: clinical and cost-effectiveness
2014	Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S)	Sutureless aortic valve replacement in patients with severe aortic valve stenosis
2014	NIHR Horizon Scanning Centre (NIHR HSC)	Pertuzumab (Perjeta) for HER2-positive locally advanced, inflammatory or early breast cancer – neo-adjuvant in combination with trastuzumab and docetaxel
2014	Canadian Agency for Drugs and Technologies in Health (CADTH)	Suboxone versus methadone for the detoxification of patients addicted to prescription opioids: a review of comparative clinical effectiveness, safety, and guidelines
2014	Institut national d'excellence en sante et en services sociaux (INESSS)	[Addendum to the notice on the efficacy of rehabilitative interventions and pharmacological therapies for children aged 2 to 12 Years with autism spectrum disorder (ASD)]
2014	University of York	Dementia carers. Effective information, support and services to meet their needs
2014	Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S)	Balloon sinuplasty for chronic rhinosinusitus
2014	NIHR Horizon Scanning Centre (NIHR HSC)	Pacritinib for myelofibrosis
2014	Canadian Agency for Drugs and Technologies in Health (CADTH)	Viscosupplementation for the treatment of osteoarthritis of the knee: clinical effectiveness and guidelines
2014	Institut national d'excellence en sante et en services sociaux (INESSS)	[Change in the Proton Pump Inhibitors (PPI) terms for coverage: a follow-up]
2014	University of York	Preventing falls in hospitals
2014	NIHR Horizon Scanning Centre (NIHR HSC)	SoftVue™ system for diagnostic breast imaging
2014	Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)	[High-dose rate brachytherapy in the treatment of mobile tongue cancer]
2014	Canadian Agency for Drugs and Technologies in Health (CADTH)	Immediate initiation of continuous positive airway pressure compared with delayed initiation: clinical effectiveness and guidelines
2014	Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S)	Implantable carotid sinus baroreflex device for treatment of drug resistant hypertension
2014	NIHR Horizon Scanning Centre (NIHR HSC)	Paclitaxel poliglumex (Xyotax) for advanced ovarian cancer – maintenance therapy
2014	Canadian Agency for Drugs and Technologies in Health (CADTH)	iTClamp for controlling compressible gemorrhage in adults: clinical effectiveness, cost-effectiveness, and safety